Unmet needs in rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue SUPPL. 82, 2009, Pages 42-46

  Bykerk, Vivian ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Diagnosis; Remission; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT;

ABSENTEEISM; BIOLOGICAL THERAPY; DISEASE COURSE; DISEASE MARKER; DRUG SUBSTITUTION; EARLY DIAGNOSIS; HEALTH CARE NEED; HUMAN; JOINT INJURY; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; PATIENT SELECTION; PREDICTION AND FORECASTING; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 67449123305     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090131     Document Type: Review

References (20)

1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
2. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
3. St. Clair EW, van der Heijde DM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-382
5. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
6. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S100-8. (Pubitemid 46657517)
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
9. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
10. Bykerk V, Smuczek J, Boire G, et al. Early rheumatoid arthritis (era) trials have almost no generalizability to era patients: results from a large multi-center cohort [abstract]. Arthritis Rheum 2008;58 Suppl:S761.
11. Treatment of early aggressive rheumatoid arthritis (TEAR). [Internet. Accessed February 13, 2009.] Available from: http://clinicaltrials.gov/ct2/show/ NCT00259610
12. Clinicaltrials.gov: Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy (RACAT). [Internet. Accessed February 23, 2009.] Available from: http://clinicaltrials.gov/ct2/ show/NCT00405275
13. Weinblatt ME, Genovese MC, Moreland LW, et al. Efficacy and safety of up to 10 years of etanercept (Enbrel®) therapy in North American patients with early and long-standing rheumatoid arthritis [abstract]. Arthritis Rheum 2007;56 Suppl:S398.
14. Hyrich KL, LuntM,Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
15. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-3235 (Pubitemid 47585417)
16. Van der Heijde D, Klareskog L, Wajdula J, Pedersen R, Fatenejad S. Sustained halting of joint damage with combination etanercept and methotrexate: 3-year results from the TEMPO trial [abstract]. Ann Rheum Dis 2006;65 Suppl II:509.
17. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-926 (Pubitemid 46999794)
18. van Vollenhoven RF, Ferraccioli G, Breedveld F, Ray S, Cifaldi M. Effect of adalimumab combination therapy on work performance: results from a companion study to PREMIER [abstract]. Ann Rheum Dis 2007;66 Suppl II:192.
19. Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
20. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008;59:757-759 (Pubitemid 351847557)